PMID- 12578870
OWN - NLM
STAT- MEDLINE
DCOM- 20030226
LR  - 20220409
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 107
IP  - 5
DP  - 2003 Feb 11
TI  - Association between plasma levels of monocyte chemoattractant protein-1 and 
      long-term clinical outcomes in patients with acute coronary syndromes.
PG  - 690-5
AB  - BACKGROUND: Monocyte chemoattractant protein-1 (MCP-1) is a chemokine responsible 
      for the recruitment of monocytes to sites of inflammation. MCP-1 appears to play 
      a critical role at multiple stages in atherosclerosis, including the initiation 
      of the fatty streak, promotion of plaque instability, and remodeling after 
      myocardial infarction. METHODS AND RESULTS: MCP-1 was measured from frozen plasma 
      specimens in 279 healthy volunteers and 2270 patients with acute coronary 
      syndromes enrolled in the Oral Glycoprotein IIb/IIIa Inhibition with Orbofiban in 
      Patients with Unstable Coronary Syndromes (OPUS-TIMI) 16 trial. Median [25th, 
      75th percentiles] MCP-1 levels were 157 [124, 196] pg/mL in healthy volunteers 
      and 178 [128, 238] pg/mL in the OPUS-TIMI 16 population (P<0.001). In OPUS-TIMI 
      16, baseline MCP-1 levels were associated with older age, female sex, 
      hypertension, diabetes, prior coronary disease, and renal insufficiency (P<0.01 
      for each) but not with smoking status, body mass index, ejection fraction, 
      troponin I or C-reactive protein. After adjustment for differences in baseline 
      characteristics, ECG changes, troponin I, and C-reactive protein, an MCP-1 level 
      >75th percentile (corresponding to the 90th percentile in the healthy volunteers) 
      was associated with an increased risk of death or myocardial infarction through 
      10 months of follow-up (adjusted hazard ratio, 1.53; 95% CI, 1.09 to 2.14; 
      P=0.01). CONCLUSIONS: In a large cohort of patients with acute coronary 
      syndromes, an elevated baseline level of MCP-1 was associated both with 
      traditional risk factors for atherosclerosis as well as an increased risk for 
      death or myocardial infarction, independent of baseline variables. Because it 
      appears to play a crucial role at multiple stages of atherosclerosis, MCP-1 is 
      attractive as a surrogate biomarker and merits further study as a potential 
      therapeutic target.
FAU - de Lemos, James A
AU  - de Lemos JA
AD  - TIMI Study Group, Donald W. Reynolds Cardiovascular Clinical Research Center, the 
      University of Texas, Southwestern Medical School, Dallas, TX 75390-9047, USA. 
      james.delemos@utsouthwestern.edu
FAU - Morrow, David A
AU  - Morrow DA
FAU - Sabatine, Marc S
AU  - Sabatine MS
FAU - Murphy, Sabina A
AU  - Murphy SA
FAU - Gibson, C Michael
AU  - Gibson CM
FAU - Antman, Elliott M
AU  - Antman EM
FAU - McCabe, Carolyn H
AU  - McCabe CH
FAU - Cannon, Christopher P
AU  - Cannon CP
FAU - Braunwald, Eugene
AU  - Braunwald E
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Biomarkers)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 0 (Pyrrolidines)
RN  - FGJ53JS7PT (orbofiban)
RN  - OF5P57N2ZX (Alanine)
SB  - IM
CIN - Circulation. 2003 Sep 9;108(10):e75. PMID: 12963689
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Alanine/therapeutic use
MH  - Biomarkers/blood
MH  - Chemokine CCL2/*blood
MH  - Cohort Studies
MH  - Confounding Factors, Epidemiologic
MH  - Coronary Disease/*blood/drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Predictive Value of Tests
MH  - Pyrrolidines/therapeutic use
MH  - Randomized Controlled Trials as Topic/statistics & numerical data
MH  - Reference Values
MH  - Risk Assessment
MH  - Risk Factors
MH  - Survival Analysis
MH  - Time
MH  - Treatment Outcome
EDAT- 2003/02/13 04:00
MHDA- 2003/02/27 04:00
CRDT- 2003/02/13 04:00
PHST- 2003/02/13 04:00 [pubmed]
PHST- 2003/02/27 04:00 [medline]
PHST- 2003/02/13 04:00 [entrez]
AID - 10.1161/01.cir.0000049742.68848.99 [doi]
PST - ppublish
SO  - Circulation. 2003 Feb 11;107(5):690-5. doi: 10.1161/01.cir.0000049742.68848.99.